Related Experiment Videos
Osteosarcoma of the pelvis.
R J Grimer1, S R Carter, R M Tillman
1Royal Orthopaedic Hospital Oncology Service, Birmingham, England, UK.
The Journal of Bone and Joint Surgery. British Volume
|October 26, 1999
Summary
Pelvic osteosarcoma survival is low, but chemotherapy and surgery improve outcomes. Early detection and treatment in younger patients offer the best chance for cure.
Area of Science:
- Oncology
- Orthopedic Surgery
Background:
- Osteosarcoma of the pelvis is a rare and aggressive bone cancer.
- It can be primary or secondary, arising after radiation or with Paget's disease.
Purpose of the Study:
- To analyze treatment outcomes for pelvic osteosarcoma over a 25-year period.
- To identify prognostic factors influencing survival in these patients.
Main Methods:
- Retrospective review of 36 patients with pelvic osteosarcoma.
- Surgical interventions included hindquarter amputation and limb-salvage procedures with intrapelvic excision.
- Chemotherapy was administered to a subset of patients.
Main Results:
- Overall 5-year survival rate was 18%.
- Patients treated with chemotherapy and surgery had a 41% 5-year survival rate.
- Secondary osteosarcoma and metastasis were associated with a very poor prognosis.
Conclusions:
- Chemotherapy combined with surgical excision offers the best chance of cure for pelvic osteosarcoma.
- Younger age, absence of metastasis, and good response to chemotherapy are favorable prognostic indicators.
- Pelvic osteosarcoma in patients over 50 years old has a dismal prognosis.